hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06339827 id: 2023-102 briefTitle: ASk Questions in GYnecologic Oncology (ASQ-GYO) acronym: ASQ-GYO overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-02 date: 2026-02 date: 2024-04-01 date: 2024-04-01 name: Ira Winer class: OTHER briefSummary: The goal of this clinical trial is to determine the effectiveness of the ASk Questions in GYnecologic Oncology question prompt list (ASQ-GYO QPL) at improving patient self-efficacy, distress, physician trust, and knowledge compared to usual care during new patient gynecologic oncology visits. Also to determine the acceptability of the ASQ-GYO QPL with new gynecologic oncology patients. conditions: Ovarian Cancer conditions: Endometrial Cancer conditions: Cervical Cancer conditions: Vulvar Cancer conditions: Vaginal Cancer conditions: Gestational Trophoblastic Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 70 type: ESTIMATED name: Administration of the ASk Questions in GYnecologic Oncology (ASQ-GYO) Question Prompt List measure: Change in pre- and post-visit self-efficacy scores and compared by trial group measure: Change in pre- and post-visit National Comprehensive Cancer Network (NCCN) Distress Thermometer scores compared by trial group measure: Change in pre- and post-visit Trust in a Physician scores compared by trial group measure: Knowledge Screen measure: Patient perceptions of the Question Prompt List sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Barbara Ann Karmanos Cancer Institute city: Detroit state: Michigan zip: 48201 country: United States name: Ira Winer, M.D. PhD role: CONTACT phone: 313-576-9194 email: iwiner@med.wayne.edu name: Elizabeth Johns role: CONTACT email: hr3132@wayne.edu name: Susan Eggly, PhD role: SUB_INVESTIGATOR name: Elizabeth Johns, MD MS role: SUB_INVESTIGATOR name: Larrissa Mattei, MD role: SUB_INVESTIGATOR name: Anna Gotschlich, PhD role: SUB_INVESTIGATOR name: Wei Chen, PhD role: SUB_INVESTIGATOR name: Sam Robinson, PhD role: SUB_INVESTIGATOR name: Ira Winer, MD PhD role: PRINCIPAL_INVESTIGATOR lat: 42.33143 lon: -83.04575 hasResults: False
nctId: NCT06339801 id: HCJSM-24-193 briefTitle: Role of Mucosal Impedance Measurement for the Diagnosis of Gastroesophageal Reflux Disease overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2025-06-01 date: 2025-08-01 date: 2024-04-01 date: 2024-04-01 name: Hospital de Clinicas José de San Martín class: OTHER briefSummary: Existing current tests for diagnosing GERD are suboptimal because they lack adequate sensitivity or specificity. Upper gastrointestinal endoscopy is highly specific for diagnosing GERD, particularly when erosive esophagitis is present (Los Angeles Classification B, C, or D). Nevertheless, its sensitivity is limited, as this scenario is only present in 30% of cases. Most patients will exhibit normal endoscopic findings, indicating Non-Erosive Reflux Disease (NERD). The 24-hour impedance-pH monitoring (MII) is currently considered the gold standard. However, its main limitation is that it can only measure reflux activity over a 24-hour period, in addition to the discomfort caused by the catheter. 6-8 It is noteworthy that 50% of patients with NERD will have pathological reflux, and the other 50% will have a sensory disorder. The importance of making an accurate diagnosis lies in the treatment, which varies in each case.11 Recently, a minimally invasive device was developed and validated in the USA to assess changes in esophageal mucosal impedance. This serves as a tool for evaluating tissue changes associated with chronic reflux. However, this device has recently undergone improvements. This new technology has not been tested yet for GERD diagnosis. The primary benefit would be the ability to diagnose GERD in symptomatic patients with NERD during the initial endoscopy conducted under sedation.
2. Evaluate the best probability score to distinguish between GERD and non-GERD Design Prospective, cross-sectional, and analytical study Study Design and Procedures The study will be conducted in the Gastroenterology Department of the Hospital de Clínicas José de San Martin, University of Buenos Aires, Argentina. Following a 4-week screening period during which a proton pump inhibitor (PPI) washout will be performed, and baseline measurements will be taken, all patients will undergo upper gastrointestinal endoscopy with mucosal impedance measurement and 24-hour impedance/pH monitoring. conditions: Gastroesophageal Reflux studyType: OBSERVATIONAL observationalModel: CASE_CROSSOVER timePerspective: PROSPECTIVE count: 100 type: ESTIMATED name: MiVu measure: diagnostic performance measure: mucosal impedance pattern measure: Correlations measure: Probability score sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06339788 id: HD-MP-106 briefTitle: Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-06 date: 2024-11 date: 2024-04-01 date: 2024-04-02 name: Handok Inc. class: INDUSTRY briefSummary: The purpose of this study is to compare the pharmacokinetics and safety of HD-P023 and coadministration of Teneligliptin and Empagliflozin in healthy adult volunteers conditions: Healthy Volunteers studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: HD-P023 name: Teneligliptin name: Empagliflozin measure: Area under the plasma concentration versus time curve (AUCt) of Teneligliptin and Empagliflozin measure: Peak Plasma Concentration (Cmax) of Teneligliptin and Empagliflozin measure: Area under the plasma concentration versus time curve zero to time infinity (AUC∞) of Teneligliptin and Empagliflozin measure: Ratio of AUCt and AUC∞ (AUCt/AUC∞) of Teneligliptin and Empagliflozin measure: Time to peak drug concentration (Tmax) of Teneligliptin and Empagliflozin measure: Volume of distribution (VZ/F) of Teneligliptin and Empagliflozin measure: Clearance (CL/F) of Teneligliptin and Empagliflozin sex: ALL minimumAge: 19 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06339775 id: 2024318 briefTitle: Blinatumomab for Relapsed Acute B Lymphoblastic Leukemia After Transplantation overallStatus: RECRUITING date: 2023-09-01 date: 2026-12-31 date: 2027-06-30 date: 2024-04-01 date: 2024-04-01 name: Suping ZHANG class: OTHER briefSummary: B-ALL patients received regular follow-up after allogeneic hematopoietic stem cell transplantation, and in case of recurrence, they were given Blinatumomab.
(MNC infusion is about 5×10\^7/kg\~1×10\^8/kg). Patients with hematologic recurrence were given Blinatumomab 9μg D1-4,11.66μg d5-7,28μg Starting from d8 （8 to 21 days in total）, followed by DLI treatment (infusion of MNC approximately 5×10\^7/kg\~1×10\^8/kg). Objective To observe and analyze the efficacy and side effects of Blinatumomab followed by donor lymphocyte infusion in patients with relapsed acute B lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation in our hospital. conditions: Acute B-cell Lymphoblastic Leukemia studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 60 type: ESTIMATED name: Blinatumomab measure: Overall survival measure: Disease-free survival measure: incidence of cytokine release syndrome （CRS） measure: Incidence of acute/chronic graft-versus-host disease （GVHD） measure: hematological adverse reactions Incidence rate sex: ALL maximumAge: 65 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: The First Affiliated Hospital of Zhengzhou University status: RECRUITING city: Zhenzhou state: Henan zip: 450000 country: China name: Suping ZHANG role: CONTACT phone: +8613523510641 email: zsp198612@163.com name: Zhilei BIAN role: CONTACT phone: 037166862272 lat: 32.28034 lon: 119.16999 typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2023-11-15 uploadDate: 2024-03-27T23:22 filename: Prot_000.pdf size: 167222 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2023-11-15 uploadDate: 2024-03-19T23:43 filename: ICF_001.pdf size: 140825 hasResults: False
nctId: NCT06339762 id: 2024/03-19 briefTitle: Self-Compassion Training Given to Relatives of Patients in Palliative Care overallStatus: RECRUITING date: 2024-02-13 date: 2024-03-13 date: 2024-04-13 date: 2024-04-01 date: 2024-04-01 name: Firat University class: OTHER briefSummary: The concept of self-compassion is a concept that has been frequently the subject of research lately and has gained importance along with positive psychology. It is also referred to as self-understanding and self-compassion in the literature. The concept of self-compassion used in our study represents the concept of self-compassion in its original form as used in foreign sources. Compassion is classified according to the source to which it is directed or received. It is suggested that there are three different flows: the feeling of compassion that the individual directs from himself to others, the feeling of compassion he receives from others, and the feeling of compassion that he directs directly to his own self. It means showing oneself the same compassion and understanding one does to others, accepting and being open to one's own pain, and being accepting of oneself without being judgmental. Individuals with self-compassion believe that the difficulties, flaws and shortcomings they experience are normal. At the same time, they are aware that being human has characteristics and that everyone can experience these situations. Individuals may be less compassionate towards themselves than they are towards others. Individuals with self-compassion are as understanding, forgiving and loving towards themselves as they are towards other people. conditions: Self-Compassion Training studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: PARTICIPANT count: 60 type: ESTIMATED name: Self-Compassion Training measure: Self-Compassion Scale: measure: Care Burden Scale: sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fırat university status: RECRUITING city: Elazığ state: Center zip: 25240 country: Turkey name: Gülcan Bahçecioğlu Turan role: CONTACT phone: 506 557 60 86 lat: 38.67431 lon: 39.22321 hasResults: False
nctId: NCT06339749 id: [2024] Ethics Review NO.040 briefTitle: Pregnancy Outcomes in Normotensive VS stage1 Hypertension: a Prospective Observational Study overallStatus: NOT_YET_RECRUITING date: 2024-04-25 date: 2025-06-30 date: 2026-02-27 date: 2024-04-01 date: 2024-04-01 name: FANG HE class: OTHER briefSummary: In 2017, the American College of Cardiology (ACC) and American Heart Association (AHA) guidelines built on evidence that elevated blood pressure increases cardiovascular mortality in the general population, Reclassification of BP; however, these diagnostic definitions do not include pregnant women, and whether newly diagnosed stage 1 hypertension affects pregnancy complications remains unclear. In this study, the combination of maternal factors, MAP and PLGF was used to comprehensively analyze the risk factors of preeclampsia through the "Bayesian rule" developed by the British Fetal Medicine Foundation (FMF). According to the guidelines and consensus, the pregnant women were considered to be at high risk when the calculated risk was higher than 1% of the population. To compare the pregnancy outcomes of women with normal blood pressure in the first trimester and stage 1 hypertension in different risk groups, and to find out whether screening for preeclampsia can be omitted for women with normal blood pressure in the first trimester, while screening for preeclampsia should still be performed for women with stage 1 hypertension as an independent moderate risk factor, and finally to optimize the screening strategy for preeclampsia. conditions: stage1 Hypertension conditions: Preeclampsia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 626 type: ESTIMATED name: blood pressure name: Clinical protocols for preeclampsia risk screening measure: preeclampsia measure: premature delivery measure: fetal intrauterine growth restriction measure: Severe complications of preeclampsia sex: FEMALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: FANG HE city: Guangzhou state: Guangdong zip: 510150 country: China name: Fang He, M.D role: CONTACT phone: +86 13724831279 email: hefangjnu@126.com name: Yafei Wang, Master role: CONTACT phone: +86 18716442633 email: 542114919@qq.com lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06339736 id: 23815 briefTitle: Treatment Outcomes in Patients With Muscular Temporo-mandibular Joint Disorders overallStatus: RECRUITING date: 2022-01-10 date: 2025-01 date: 2025-12 date: 2024-04-01 date: 2024-04-01 name: University of Pisa class: OTHER briefSummary: The aim of the present study was to assess the treatment outcomes in patients affected by M-TMDs in terms of pain scores assessed with pressure pain threshold (PPT). The levels of de-pression, anxiety and the Oral-Health Impact profile were also assessed and compared to healthy controls. Patients with a clinical diagnosis of M-TMDs and a control group of healthy subjects were enrolled. At baseline, OHIP-14, PHQ-9 and GAD-7 were administered. PPT was registered at the level of masseter and temporalis muscles. The patients were then treated with oral splints and physio-kinesiotherapy following a standardized treatment protocol. At 6-months follow-up, PPT was registered, and the questionnaires were re-administered to compare treatment outcomes. conditions: TMD conditions: TMD/Orofacial Pain studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 120 type: ESTIMATED name: Questionnaires administered to all study participants measure: Evaluation of the impact of muscular pain on oral health measure: Evaluation of the impact of muscular pain on anxiety measure: Evaluation of the impact of muscular pain on depression measure: Changes in muscular pain sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Pisa status: RECRUITING city: Pisa zip: 56126 country: Italy name: Rossana Izzetti role: CONTACT phone: +39050993037 email: rossana.izzetti@unipi.it name: Rossana Izzetti role: PRINCIPAL_INVESTIGATOR lat: 43.70853 lon: 10.4036 hasResults: False
nctId: NCT06339723 id: 2024/03-17 briefTitle: Pecha Kuka Method About Percutaneous Endoscopic Gastrostomy for Caregivers Who Care for Palliative Care Patients overallStatus: RECRUITING date: 2024-02-13 date: 2024-03-13 date: 2024-04-13 date: 2024-04-01 date: 2024-04-01 name: Firat University class: OTHER briefSummary: Palliative care; It was started by Dame Cicely Saunders in the 1960s as a hospice for community-based provision. Today, palliative care is defined as care that begins with the patient's diagnosis, symptom management is carried out effectively, and a comprehensive, supportive, humanistic approach is based on the individual and his family. When the literature was examined, no study was found that evaluated the effectiveness of the training given by the Pecha Kuka method to caregivers caring for palliative care patients about percutaneous endoscopic gastrostomy. In addition, it is thought that the results of this research will shed light on identifying problems related to feeding practices in patients fed with PEG tubes and identifying misinformation and practices of caregivers. Determining the knowledge level and initiatives of caregivers regarding percutaneous endoscopic gastrostomy tube feeding practices will contribute to the development of educational activities and effective strategies. Study results may provide important data regarding improving the quality of care given to patients and caregivers after discharge and controlling complication rates. conditions: Pecha Kuka conditions: Palliative Care studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: SINGLE whoMasked: PARTICIPANT count: 60 type: ESTIMATED name: Pecha Kucha measure: Evaluation Form for Feeding Practices with Percutaneous Endoscopic Gastrostomy Tube: measure: Visual Analog Scale -Anxiety: sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fırat university status: RECRUITING city: Elazığ state: Center zip: 25240 country: Turkey name: Gülcan Bahçecioğlu Turan role: CONTACT phone: 506 557 60 86 lat: 38.67431 lon: 39.22321 hasResults: False
nctId: NCT06339710 id: U1111-1288-5508 briefTitle: Short Benznidazole Regimen for Chronic Phase Chagas Disease Patients acronym: Benlatino overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-01-30 date: 2026-10-30 date: 2024-04-01 date: 2024-04-01 name: Evandro Chagas Institute of Clinical Research class: OTHER briefSummary: Multicentric study on Chagas disease that seeks to evaluate a new treatment regimen using the drug benznidazole. Currently, existing treatment regimens are long and have frequent side effects, which leads to a high dropout rate among patients. The research proposes testing two shorter benznidazole regimens to see if they are as effective as standard treatment, but with fewer side effects.
The study will have 672 participants and will be carried out in four locations, Bolivia and Colombia. The objective is to analyze the efficacy and safety of new treatment regimens, evaluating the parasitological response in comparison with standard treatment. In addition, an economic assessment will be carried out to analyze direct and indirect costs, including procedures associated with the management of adverse events. conditions: Chronic Chagas Disease studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 672 type: ESTIMATED name: benznidazole 300 mg daily 8 weeks measure: Proportion of participants with sustained negative Polymerase Chain Reaction (PCR) during the 24 months of follow-up after treatment. measure: Incidence of Adverse Events (AE) leading to treatment discontinuation during treatment period measure: Proportion of participants with positive PCR at different time points measure: Incidence and severity of clinically relevant events attributed to Chagas disease measure: To measure the quality of life (QoL) of participants measure: To measure the quality of life (QoL) of participants sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Israel Molina city: Minas Gerais state: Belo Horizonte country: Brazil name: CARLA Renata TREVIA role: CONTACT phone: 21996670525 email: renatasantos@cuidachagas.org name: Monique MG Gurgel, Master role: CONTACT phone: +55 21 997248094 email: moniquegurgel@cuiachagas.org name: Andrea Silvestre De Sousa, PHD role: PRINCIPAL_INVESTIGATOR lat: -8.96667 lon: -72.78333 facility: Carla Renata Ferreira Dos Santos Trevia city: Rio De Janeiro state: RJ zip: 22631390 country: Brazil name: Israel IM Molina, PHD role: CONTACT phone: +34 679337605 email: israel.molina@fiocruz.gov name: Monique MG Gurgel, Master role: CONTACT phone: +55 21 997248094 email: moniquegurgel@uidachagas.gov lat: -22.90278 lon: -43.2075 facility: Carla Renata Ferreira dos Santos Trevia city: Rio de Janeiro state: RJ zip: 22790-790 country: Brazil name: Israel IM Molina, PHd role: CONTACT phone: +34 679 33 76 05 email: israel.molina@fiocruz.gov name: Monique MG Gurgel, Master role: CONTACT phone: +55 21 name: Israel IM Molina, PHD role: PRINCIPAL_INVESTIGATOR name: Ana Gabriela AH Herrera, PHD role: PRINCIPAL_INVESTIGATOR name: Maria Ximena MX Escalante Lazcano, PHD role: PRINCIPAL_INVESTIGATOR name: Mario MO Mario Oliveira role: PRINCIPAL_INVESTIGATOR name: Juan JV Carlos Villar role: PRINCIPAL_INVESTIGATOR lat: -22.90278 lon: -43.2075 typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2023-02-14 uploadDate: 2024-03-19T19:03 filename: Prot_000.pdf size: 1319333 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2023-02-14 uploadDate: 2024-03-19T18:18 filename: ICF_001.pdf size: 392791 hasResults: False
nctId: NCT06339697 id: 2022-KY-233 briefTitle: Short-term Effects of Bowel Preparation on Gut Microbiome in Patients Undergoing Endoscopic Colon Polypectomy overallStatus: COMPLETED date: 2022-12-01 date: 2023-06-30 date: 2023-06-30 date: 2024-04-01 date: 2024-04-01 name: Zhang Yanli class: OTHER briefSummary: To investigate the role of different types of laxatives (compounded polyethylene glycol electrolyte dispersions and compounded sodium pico-sulfate) on the composition, evolution and recovery of the gut microbiome of patients with colonic polyps undergoing bowel preparation. conditions: Colon Polyp conditions: Cathartic Colon studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 194 type: ACTUAL name: different types of laxatives (compounded polyethylene glycol electrolyte dispersions and compounded sodium pico-sulfate) measure: gut microbiome-taxonomy measure: gut microbiome-heatmap measure: gut microbiome-Alpha Diversity measure: gut microbiome-Beta Diversity measure: gut microbiome-Functional predictions measure: Age measure: Gender measure: Height measure: Weight measure: BMI measure: Whether the enrollee is a smoker measure: Whether the enrollee is a drinker measure: Evaluation of the effectiveness of intestinal cleansing Evaluation of the effectiveness of intestinal cleansing measure: Gastrointestinal Symptom Score measure: adverse event sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: China-Japan Friendship Hospital city: Beijing state: Beijing zip: 100029 country: China lat: 39.9075 lon: 116.39723 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2022-12-01 uploadDate: 2024-03-20T22:22 filename: Prot_SAP_000.pdf size: 135642 hasResults: False
nctId: NCT06339684 id: 2021 0075257 briefTitle: HPV Immunological Markers of Cervical Persistent Infection and Oncogenesis acronym: HPVImmuno overallStatus: ACTIVE_NOT_RECRUITING date: 2023-03-08 date: 2026-03-08 date: 2026-03-08 date: 2024-04-01 date: 2024-04-03 name: Foundation IRCCS San Matteo Hospital class: OTHER briefSummary: The aim of this observational study is to build an immunological assay to quantify an immunoscore system for clinical practice, which could identify HPV lesions with a risk of persistent cervical infection, which represents the main predictive factor of neoplastic evolution. A pattern of host immunological factors and HPV-related parameters, in order to identify an algorithm of risk stratification and tailoring treatment will be identified. Finally, in patients with HPV infection, a virus specific immunity after vaccination will be quantified, in order to highlight those patients who have the most significant risk of infection persistence. conditions: HPV-Related Cervical Carcinoma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 120 type: ACTUAL measure: Analysis plan for primary end-point measure: Analysis plan for secondary end-points sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fondazione IRCCS Policlinico San Matteo city: Pavia country: Italy lat: 45.19205 lon: 9.15917 hasResults: False